Policy & Geopolitics
Axsome Surges 20% to All-Time High on FDA Priority Review for Alzheimer's Drug
Dec 31, 2025
You're signed outSign in or to get full access.
AT
Axsome Therapeutics (AXSM)·Earnings Reports
Q4 2024
View earnings summary and analysis
Q3 2024
View earnings summary and analysis
Q2 2024
View earnings summary and analysis
Q1 2024
View earnings summary and analysis
Research analysts covering Axsome Therapeutics.